P
Paul R. Lockman
Researcher at West Virginia University
Publications - 117
Citations - 7367
Paul R. Lockman is an academic researcher from West Virginia University. The author has contributed to research in topics: Blood–brain barrier & Brain metastasis. The author has an hindex of 38, co-authored 109 publications receiving 6249 citations. Previous affiliations of Paul R. Lockman include Texas Tech University Health Sciences Center & Texas Tech University.
Papers
More filters
Journal ArticleDOI
Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio
Tianzhi Yang,Paige Martin,Brittany Fogarty,Alison Brown,Kayla Schurman,Roger J. Phipps,Viravuth P. Yin,Paul R. Lockman,Shuhua Bai,Shuhua Bai +9 more
TL;DR: Brain endothelial cell derived exosomes could be potentially used as a carrier for brain delivery of anticancer drug for the treatment of brain cancer.
Journal ArticleDOI
Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability
TL;DR: In this article, the effect of neutral, anionic and cationic charged nanoparticles on the blood-brain barrier (BBB) and brain permeability was evaluated by in situ rat brain perfusion.
Journal ArticleDOI
Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman,Rajendar K. Mittapalli,Kunal S Taskar,Vinay Rudraraju,Brunilde Gril,Kaci A. Bohn,Chris E. Adkins,Amanda Roberts,Helen R. Thorsheim,Julie A. Gaasch,Suyun Huang,Diane Palmieri,Patricia S. Steeg,Quentin R. Smith +13 more
TL;DR: This work shows that the BTB remains a significant impediment to standard chemotherapeutic delivery and efficacy in experimental brain metastases of breast cancer, and new brain permeable drugs will be needed.
Journal ArticleDOI
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
TL;DR: NP technology appears to have significant promise in delivering therapeutic molecules across the blood-brain barrier and primary methods of NP preparation and characterization are described.
Journal ArticleDOI
Paclitaxel nanoparticles for the potential treatment of brain tumors
TL;DR: It was hypothesized that PX NPs could mask paclitaxel characteristics and thus limit its binding to p-gp, which consequently would lead to higher brain and tumor cell uptake of the otherwise effluxed drug.